DGAP-News: Eckert & Ziegler Records Solid Half-Year Results. Growth Trend for Radiopharmaceuticals Remains Intact.


 

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year Results
Eckert & Ziegler Records Solid Half-Year Results. Growth Trend for Radiopharmaceuticals Remains Intact.

13.08.2020 / 07:45
The issuer is solely responsible for the content of this announcement.


Berlin, 13 August 2020. Despite heavy burdens from corona and the drop in oil price, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), a specialist for isotope applications in medicine, science and industry, closed the first half of 2020 with a net income of 12.7 million EUR, almost reaching the record level of the previous year (13.1 million EUR). Revenues amounted to EUR 83.6 million and were thus 6% below the previous year's level.

The main reason for the relatively steady performance was the continued strong growth, compared to the previous year, in sales and earnings from radiopharmaceutical products and services in the Medical segment. While laboratory equipment and brachytherapy sources, including iodine implants, suffered considerably from reduced orders from hospitals due to the coronavirus crisis, half-year sales of pharmaceutical radioisotopes increased by more than € 4 million, or almost 30%, to just under € 20 million.

In contrast, the Isotope Products segment, due to Corona, could not maintain the high sales level of the same period of the previous year and achieved sales of EUR 47.1 million, which is EUR 8.3 million or about 15% lower than in the first half of 2019. Declining revenues particularly affected the lucrative components for industrial measurement technology, the Brazilian business and waste management services. Slight increases were only recorded in medical devices components and raw materials trading.

With the figures for the first half of the year, the Eckert & Ziegler Group has largely met, and in the case of net profit for the period, even exceeded the budget targets for the current financial year, as revised due to the coronavirus crisis.

Taking into account one-off effects and the expectation that the impact of the corona pandemic will not change dramatically, the Executive Board expects revenues of EUR 170 million and a net income of at least EUR 20 million to be achieved in the FY 2020.

The complete financial statements can be viewed here:
http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz220e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com



13.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1116459

 
End of News DGAP News Service

1116459  13.08.2020 

fncls.ssp?fn=show_t_gif&application_id=1116459&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 137,94 138,63 168,71 178,49 176,14 178,00 0,00
EBITDA1,2 24,97 26,62 32,14 43,13 44,64 0,00 0,00
EBITDA-Marge3 18,10 19,20 19,05 24,16 25,34 0,00 0,00
EBIT1,4 16,23 17,97 23,39 32,06 33,69 0,00 0,00
EBIT-Marge5 11,77 12,96 13,86 17,96 19,13 0,00 0,00
Jahresüberschuss1 9,79 15,12 16,89 22,48 23,11 29,60 0,00
Netto-Marge6 7,10 10,91 10,01 12,59 13,12 16,63 0,00
Cashflow1,7 19,83 26,83 21,21 40,43 36,79 0,00 0,00
Ergebnis je Aktie8 0,45 0,70 0,78 1,07 1,11 1,70 1,93
Dividende8 0,17 0,20 0,30 0,42 0,45 0,48 0,60
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

XETR:EUZ Charts by TradingView (c)


INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 81,350 Halten 1.722,34
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
31,29 23,95 1,34 112,05
KBV KCV KUV EV/EBITDA
10,06 46,82 9,78 36,80
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,45 0,48 0,59 01.06.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
12.05.2022 11.08.2022 09.11.2021 30.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-21,91% -21,34% -13,55% 66,91%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei DGAP abrufen


Medtech , 565970 , EUZ , XETR:EUZ